TOPICAL FORMULATION FOR A JAK INHIBITOR
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
1 .- 82 . (canceled)
83 . A pharmaceutical composition for topical skin application to a human patient, comprising:
(1) about 0.5% to about 1.5% by weight of the composition, on a free base basis, of 1:1 (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt, and
(2) a means for effecting skin permeation of the phosphoric acid salt to the patient.
84 . The composition according to claim 83 , wherein the composition is for application to the patient's skin for up to 84 consecutive days.
85 . A pharmaceutical composition for topical skin application to a human patient, comprising:
(1) about 0.5% by weight of the composition, on a free base basis, of 1:1 (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt, and
(2) a means for effecting skin permeation of the phosphoric acid salt to the patient.
86 . A pharmaceutical composition for topical skin application to a human patient, comprising:
(1) about 1.0% by weight of the composition, on a free base basis, of 1:1 (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt, and
(2) a means for effecting skin permeation of the phosphoric acid salt to the patient.
87 . A pharmaceutical composition for topical skin application to a human patient, comprising:
(1) about 1.5% by weight of the composition, on a free base basis, of 1:1 (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt, and
(2) a means for effecting skin permeation of the phosphoric acid salt to the patient.